Q4 2018 Viking Therapeutics Inc Earnings Call
שיחת ועידה Viking Therapeutics Inc
Viking Therapeutics Inc Conference call will be held on 13/03/2019. During the earnings conference call's session Viking Therapeutics Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Viking Therapeutics Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
We are a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. We have exclusive worldwide rights to a portfolio of five drug candidates in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated, or Ligand. Details regarding our license agreement with Ligand are discussed in the section of this Prospectus entitled "--Agreements with Ligand". Our lead clinical program is VK5211, an orally available drug candidate, currently in a Phase 2 clinical trial for acute rehabilitation following non-elective hip fracture surgery. Hip fracture is a common injury among persons aged 60 and older.קרא עוד שיחת ועידה